Galen Cheng

Galen Cheng

Auto-generated profile, based on publicly available information

Galen Cheng

University of Rochester Medical Center, Rochester, New York, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2019 in JCI Insight
Verified
Journal Article
Closed access
PDF file
SGStefanie Geisler
Stefanie Geisler
RDRyan A. Doan
Ryan A. Doan
GCGalen C. Cheng
Galen C. Cheng
ACAysel Cetinkaya-Fisgin
Aysel Cetinkaya-Fisgin
SHShay X. Huang
Shay X. Huang
ADAaron DiAntonio
Aaron DiAntonio
Chemotherapy-induced peripheral neuropathy is one of the most prevalent dose-limiting toxicities of anticancer therapy. Development of effective therapies to prevent chemotherapy-induced neuropathies could be enabled by a mechanistic understanding of axonal breakdown following exposure to neuropathy-causing agents. Here, we reveal the molecular mechanisms underlying axon degeneration induced by 2 widely used chemotherapeutic agents with distinct mechanisms of action: vincristine and bortezomib. We showed previously that genetic deletion of SARM1 blocks vincristine-induced neuropathy and demonstrate here that it also prevents axon destruction following administration of bortezomib in vitro and in vivo. Using cultured neurons, we found that vincristine and bortezomib converge on a core axon degeneration program consisting of nicotinamide mononucleotide NMNAT2, SARM1, and loss of NAD + but engage different upstream mechanisms that closely resemble Wallerian degeneration after vincristine and apoptosis after bortezomib. We could inhibit the final common axon destruction pathway by preserving axonal NAD + levels or expressing a candidate gene therapeutic that inhibits SARM1 in vitro. We suggest that these approaches may lead to therapies for vincristine- and bortezomib-induced neuropathies and possibly other forms of peripheral neuropathy.

26 April 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LZLifei Zhu
Lifei Zhu
GCGalen Cheng
Galen Cheng
DYDezhuang Ye
Dezhuang Ye
ANArash Nazeri
Arash Nazeri
YYYimei Yue
Yimei Yue
HCHong Chen
Hong Chen
Although blood-based liquid biopsies have emerged as a promising non-invasive method to detect biomarkers in various cancers, limited progress has been made for brain tumors. One major obstacle is the blood-brain barrier (BBB), which hinders efficient passage of tumor biomarkers into the peripheral circulation. The objective of this study was to determine whether FUS in combination with microbubbles can enhance the release of biomarkers from the brain tumor to the blood circulation. Two glioblastoma tumor models (U87 and GL261), developed by intracranial injection of respective enhanced green fluorescent protein (eGFP)-transduced glioblastoma cells, were treated by FUS in the presence of systemically injected microbubbles. Effect of FUS on plasma eGFP mRNA levels was determined using quantitative polymerase chain reaction. eGFP mRNA were only detectable in the FUS-treated U87 mice and undetectable in the untreated U87 mice (maximum cycle number set to 40). This finding was replicated in GL261 mice across three different acoustic pressures. The circulating levels of eGFP mRNA were 1,500–4,800 fold higher in the FUS-treated GL261 mice than that of the untreated mice for the three acoustic pressures. This study demonstrated the feasibility of FUS-enabled brain tumor liquid biopsies in two different murine glioma models across different acoustic pressures.

4 January 2018 in International Journal of Hyperthermia
Verified
Journal Article
Closed access
SKSatya V. V. N. Kothapalli
Satya V. V. N. Kothapalli
MAMichael B. Altman
Michael B. Altman
LZLifei Zhu
Lifei Zhu
APAri Partanen
Ari Partanen
GCGalen Cheng
Galen Cheng
HCHong Chen
Hong Chen
Purpose: Since mild hyperthermia therapy (MHT) requires maintaining the temperature within a narrow window (e.g. 40–43 °C) for an extended duration (up to 1 h), accurate and precise temperature measurements are essential for ensuring safe and effective treatment. This study evaluated the precision and accuracy of MR thermometry in healthy volunteers at different anatomical sites for long scan times. Methods: A proton resonance frequency shift method was used for MR thermometry. Eight volunteers were subjected to a 5-min scanning protocol, targeting chest wall, bladder wall, and leg muscles. Six volunteers were subjected to a 30-min scanning protocol and three volunteers were subjected to a 60-min scanning protocol, both targeting the leg muscles. The precision and accuracy of the MR thermometry were quantified. Both the mean precision and accuracy <1 °C were used as criteria for acceptable thermometry. Results: Drift-corrected MR thermometry measurements based on 5-min scans of the chest wall, bladder wall, and leg muscles had accuracies of 1.41 ± 0.65, 1.86 ± 1.20, and 0.34 ± 0.44 °C, and precisions of 2.30 ± 1.21, 1.64 ± 0.56, and 0.48 ± 0.05 °C, respectively. Measurements based on 30-min scans of the leg muscles had accuracy and precision of 0.56 ± 0.05 °C and 0.42 ± 0.50 °C, respectively, while the 60-min scans had accuracy and precision of 0.49 ± 0.03 °C and 0.56 ± 0.05 °C, respectively. Conclusions: Respiration, cardiac, and digestive-related motion pose challenges to MR thermometry of the chest wall and bladder wall. The leg muscles had satisfactory temperature accuracy and precision per the chosen criteria. These results indicate that extremity locations may be preferable targets for MR-guided MHT using the existing MR thermometry technique.

1 August 2024 in Journal of Endourology
Verified
Journal Article
Closed access
JLJixuan Leng
Jixuan Leng
JLJunfei Liu
Junfei Liu
GCGalen Cheng
Galen Cheng
HWHaohan Wang
Haohan Wang
SQScott Quarrier
Scott Quarrier
RJRajat Jain
Rajat Jain
Introduction: Chemical composition analysis is important in prevention counseling for kidney stone disease. Advances in laser technology have made dusting techniques more prevalent, but this offers no consistent way to collect enough material to send for chemical analysis, leading many to forgo this test. We developed a novel machine learning (ML) model to effectively assess stone composition based on intraoperative endoscopic video data. Methods: Two endourologists performed ureteroscopy for kidney stones ≥ 10 mm. Representative videos were recorded intraoperatively. Individual frames were extracted from the videos, and the stone was outlined by human tracing. An ML model, UroSAM, was built and trained to automatically identify kidney stones in the images and predict the majority stone composition as follows: calcium oxalate monohydrate (COM), dihydrate (COD), calcium phosphate (CAP), or uric acid (UA). UroSAM was built on top of the publicly available Segment Anything Model (SAM) and incorporated a U-Net convolutional neural network (CNN). Discussion: A total of 78 ureteroscopy videos were collected; 50 were used for the model after exclusions (32 COM, 8 COD, 8 CAP, 2 UA). The ML model segmented the images with 94.77% precision. Dice coefficient (0.9135) and Intersection over Union (0.8496) confirmed good segmentation performance of the ML model. A video-wise evaluation demonstrated 60% correct classification of stone composition. Subgroup analysis showed correct classification in 84.4% of COM videos. A post hoc adaptive threshold technique was used to mitigate biasing of the model toward COM because of data imbalance; this improved the overall correct classification to 62% while improving the classification of COD, CAP, and UA videos. Conclusions: This study demonstrates the effective development of UroSAM, an ML model that precisely identifies kidney stones from natural endoscopic video data. More high-quality video data will improve the performance of the model in classifying the majority stone composition.

7 December 2022 in Urolithiasis
Verified
Journal Article
Closed access
PDF file
GCGalen Cheng
Galen Cheng
TCTimothy Campbell
Timothy Campbell
CFChangyong Feng
Changyong Feng
SQScott Quarrier
Scott Quarrier
RJRajat Jain
Rajat Jain